LUPIN

Recent News & Updates

📌 Lupin Stock – Recent News & Updates (December 2025) 📈 Stock Performance Lupin has been trading in the ₹2,000–₹2,100 range recently. The stock has been relatively stable but slightly volatile because of U.S. regulatory updates. It remains closer to its upper band of the past year, showing overall sustained strength. 🧪 Business & Product Updates ✔️ New Approvals in the U.S. Market Lupin recently received approval for a biosimilar version of pegfilgrastim, strengthening its footprint in the high-value U.S. biosimilars segment. The company also launched an authorized generic version of Ravicti Oral Liquid in the U.S. market, which should support revenue growth in its specialty/generics portfolio. ✔️ Focus on International Formulations Lupin continues to expand its U.S. and Europe product pipelines, which remain key contributors to its revenue. The company is also pushing to improve margins through complex generics and biosimilars. 🏭 Regulatory Updates ⚠️ USFDA Observations Lupin’s Nagpur facility recently received multiple observations from the USFDA after an inspection. This caused a short-term dip in the stock, as investors are cautious whenever regulatory issues appear.